{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:50:05Z","timestamp":1775296205697,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T00:00:00Z","timestamp":1470441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40265-016-0623-y","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T05:22:15Z","timestamp":1470460935000},"page":"1293-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Opicapone: A Review in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"76","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,6]]},"reference":[{"issue":"362","key":"623_CR1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"2004","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt J, Ransom RR, et al. Parkinson\u2019s disease. Lancet. 2004;2004(362):1783\u201393.","journal-title":"Lancet"},{"issue":"23","key":"623_CR2","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"PA LeWitt","year":"2008","unstructured":"LeWitt PA. Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med. 2008;359(23):2468\u201376.","journal-title":"N Engl J Med"},{"issue":"2","key":"623_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","volume":"75","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75(2):157\u201374.","journal-title":"Drugs."},{"key":"623_CR4","unstructured":"European Medicines Agency. Ongentys 25\u00a0mg hard capsules: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 12 July 2016."},{"issue":"8","key":"623_CR5","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396\u2013411.","journal-title":"J Med Chem"},{"issue":"7","key":"623_CR6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/bph.13020","volume":"172","author":"MJ Bonifacio","year":"2015","unstructured":"Bonifacio MJ, Torrao L, Loureiro AI, et al. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015;172(7):1739\u201352.","journal-title":"Br J Pharmacol"},{"key":"623_CR7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.neuropharm.2013.10.014","volume":"77","author":"MJ Bonifacio","year":"2014","unstructured":"Bonifacio MJ, Sutcliffe JS, Torrao L, et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology. 2014;77:334\u201341.","journal-title":"Neuropharmacology"},{"issue":"2","key":"623_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha JF, Falcao A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139\u201351.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"623_CR9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falcao A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763\u201375.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"623_CR10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cpdd.213","volume":"5","author":"A Falc\u00e3o","year":"2016","unstructured":"Falc\u00e3o A, Rocha JF, Santos A, et al. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. Clin Pharmacol Drug Dev. 2016;5(2):150\u201361.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"623_CR11","unstructured":"Ferreira JJ, Rocha JF, Falcao A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson\u2019s disease. Eur J Neurol. 2015;22(5):815-25, e56."},{"issue":"3","key":"623_CR12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/cpdd.217","volume":"5","author":"J-F Rocha","year":"2015","unstructured":"Rocha J-F, Ferreira JJ, Falcao A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2015;5(3):232\u201340.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"623_CR13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","volume":"70","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Falcao A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70:1059\u201371.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"623_CR14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cpdd.188","volume":"4","author":"R Pinto","year":"2015","unstructured":"Pinto R, l\u2019Hostis P, Patat A, et al. Evaluation of opicapone on cardiac repolarization in a thorough QT\/QTc study. Clin Pharmacol Drug Develop. 2015;4(6):454\u201362.","journal-title":"Clin Pharmacol Drug Develop."},{"issue":"3","key":"623_CR15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00228-013-1602-9","volume":"70","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Santos A, Falcao A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014;70(3):279\u201386.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"623_CR16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365.","journal-title":"Lancet Neurol"},{"key":"623_CR17","unstructured":"Bial-Portela & Ca, S.A. NCT01227655. 2015. http:\/\/www.clinicaltrials.gov\/ . Accessed 12 Jul 2016."},{"issue":"Suppl 1","key":"623_CR18","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jns.2013.07.391","volume":"333","author":"A Lees","year":"2013","unstructured":"Lees A, Ferreira JJ, Costa R, et al. Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson\u2019s disease patients: BIPARK-II study [abstract no. 1038]. J Neurol Sci. 2013;333(Suppl 1):e116.","journal-title":"J Neurol Sci"},{"issue":"Suppl 1","key":"623_CR19","first-page":"S173","volume":"30","author":"C Oliveira","year":"2015","unstructured":"Oliveira C, Lees A, Ferreira J, et al. Opicapone and non-motor symptoms in Parkinson\u2019s disease: results from a double-blind, randomized, placebo-controlled study and open-label extension. Mov Disord. 2015;30(Suppl 1):S173.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR20","first-page":"S86","volume":"30","author":"J Ferreira","year":"2015","unstructured":"Ferreira J, Lees A, Santos A, et al. Efficacy of opicapone as adjunctive therapy to levodopa in patients with Parkinson\u2019s disease and motor fluctuations: analysis of pooled phase III studies. Mov Disord. 2015;30(Suppl 1):S86.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR21","first-page":"S99","volume":"30","author":"A Lees","year":"2015","unstructured":"Lees A, Ferreira J, Lopes N, et al. Efficacy and safety of opicapone in patients over 70\u00a0years with Parkinsons disease and motor fluctuations. Mov Disord. 2015;30(Suppl 1):S99.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR22","first-page":"S101","volume":"30","author":"N Lopes","year":"2015","unstructured":"Lopes N, Ferreira J, Lees A, et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinsons disease. Mov Disord. 2015;30(Suppl 1):S101.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR23","first-page":"S642","volume":"31","author":"A Lees","year":"2016","unstructured":"Lees A, Ferreira J, Muller T, et al. Opicapone in fluctuating Parkinson\u2019s disease patients: OFF- and ON-time responder post hoc analyses of pooled phase III studies [abstract no. 1953]. Mov Disord. 2016;31(Suppl 2):S642.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR24","first-page":"S642","volume":"31","author":"A Lees","year":"2016","unstructured":"Lees A, Ferreira J, Reichmann H, et al. Onset and stabilization of treatment effects in fluctuating Parkinson\u2019s disease patients: exploratory by-week efficacy analysis of pooled phase III studies [abstract no. 1954]. Mov Disord. 2016;31(Suppl 2):S642.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR25","first-page":"S642","volume":"31","author":"N Lopes","year":"2016","unstructured":"Lopes N, Ferreira J, Lees A, et al. Exploratory efficacy of opicapone in fluctuating Parkinson\u2019s disease patients at different stages of symptom progression [abstract no. 1955]. Mov Disord. 2016;31(Suppl 2):S642.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR26","first-page":"S633","volume":"31","author":"J Ferreira","year":"2016","unstructured":"Ferreira J, Lees A, Tolosa E, et al. Switching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I [abstract no. 1925]. Mov Disord. 2016;31(Suppl 2):S633.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR27","first-page":"S643","volume":"31","author":"J Ferreira","year":"2016","unstructured":"Ferreira J, Lees A, Rascol O, et al. Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson\u2019s disease treated with opicapone [abstract no. 1956]. Mov Disord. 2016;31(Suppl 2):S643.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR28","first-page":"S233","volume":"29","author":"R Costa","year":"2014","unstructured":"Costa R, Oliveira C, Pinto R, et al. One-year open-label efficacy and safety of opicapone in Parkinson\u2019s disease BIPARK-II study. Mov Disord. 2014;29(Suppl 1):S233.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR29","first-page":"S86","volume":"30","author":"J Ferreira","year":"2015","unstructured":"Ferreira J, Lees A, Gama H, et al. Safety and tolerability of opicapone in the treatment of Parkinson\u2019s disease and motor fluctuations: analysis of pooled phase III studies. Mov Disord. 2015;30(Suppl 1):S86.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR30","first-page":"S99","volume":"30","author":"A Lees","year":"2015","unstructured":"Lees A, Ferreira J, Costa R, et al. 1-year safety of opicapone in patients with Parkinson\u2019s disease and motor fluctuations [abstract no. 257]. Mov Disord. 2015;30(Suppl 1):S99.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR31","first-page":"S101","volume":"30","author":"N Lopes","year":"2015","unstructured":"Lopes N, Ferreira J, Lees A, et al. Hepatic safety of opicapone in Parkinson\u2019s disease patients. Mov Disord. 2015;30(Suppl 1):S101.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR32","first-page":"S643","volume":"31","author":"N Lopes","year":"2016","unstructured":"Lopes N, Ferreira J, Lees A, et al. Evaluation of impulse of control disorders in fluctuating Parkinson\u2019s disease patients under opicapone treatment [abstract no. 1957]. Mov Disord. 2016;31(Suppl 2):S643.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"623_CR33","first-page":"S112","volume":"30","author":"R Pinto","year":"2015","unstructured":"Pinto R, Vaz-da-Silva M, Lopes N, et al. Cardiac safety of opicapone in patients with Parkinson\u2019s disease: analysis of the centralized phase III ECG dataset. Mov Disord. 2015;30(Suppl 1):S112.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"623_CR34","first-page":"641","volume":"31","author":"A Santos","year":"2016","unstructured":"Santos A, Ferreira J, Lees A, et al. Safety of opicapone in fluctuating Parkinson\u2019s disease patients: results of the 1-year extension of study BIPARK I [abstract no. 1949]. Mov Disord. 2016;31(Suppl 2):641.","journal-title":"Mov Disord"},{"key":"623_CR35","doi-asserted-by":"crossref","first-page":"g6258","DOI":"10.1136\/bmj.g6258","volume":"349","author":"CG Goetz","year":"2014","unstructured":"Goetz CG, Pal G. Initial management of Parkinson\u2019s disease. Br Med J. 2014;349:g6258.","journal-title":"Br Med J"},{"key":"623_CR36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol. 2013;20:5\u201315.","journal-title":"Eur J Neurol"},{"key":"623_CR37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/bmj.39289.437454.AD","volume":"335","author":"CE Clarke","year":"2007","unstructured":"Clarke CE. Parkinson\u2019s disease. Br Med J. 2007;335:441\u20135.","journal-title":"Br Med J"},{"issue":"5","key":"623_CR38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson\u2019s disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384\u20136.","journal-title":"Neurology."},{"key":"623_CR39","unstructured":"National Institute for Health and Clinical Excellence. Parkinson\u2019s disease in over 20\u00a0s: diagnosis and management. 2006. http:\/\/www.nice.org.uk\/guidance\/cg35 . Accessed 22 June 2016."},{"key":"623_CR40","unstructured":"European Medicines Agency. Stalevo 50\u00a0mg\/12.5\u00a0mg\/200\u00a0mg film-coated tablets: summary of product characteristics 2008. http:\/\/www.ema.europa.eu . Accessed 24 June 2016."}],"updated-by":[{"DOI":"10.1007\/s40265-016-0637-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T00:00:00Z","timestamp":1472860800000}},{"DOI":"10.1007\/s40265-017-0847-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0623-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0623-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0623-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:06:48Z","timestamp":1498334808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0623-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,6]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0623-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-017-0847-5","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s40265-016-0637-5","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,6]]}}}